[Survival time and related factors on HIV/AIDS patients in Guizhou province from 1995 to 2018].

To examine the survival time and related factors on HIV/AIDS patients in Guizhou province from 1995 to 2018. A retrospective cohort study was conducted to analyze the HIV/AIDS case from 1995 to 2018 in Guizhou province with data gathered from the "Chinese National Comprehensive HIV/AIDS Prevention and care Information system". Survival rate was calculated by life table and survival time was estimated by Kaplan-Meier. Related factors on survival time were analyzed by Cox regression model. A total of 53 232 HIV/AIDS cases were included in the study, with the mortality rate as 8.53/100 person-years (14 210/166 679.18), median survival time as 10.20 (95: 9.91-10.48) years, and survival rates of 1, 5, 10 and 20 years as 0.85, 0.68, 0.51, 0.36, 0.19 respectively. Results from the multivariate Cox regression analysis showed that factors as: being male (compared with females, a=0.757, 95: 0.727-0.788), with antiviral treatment (ART) (compared with those without ART, a=0.173, 95: 0.165-0.181), CD(4)<200 cells/μl[compared with CD(4)(+)T cells (CD(4)) ≥200 cells/μl, a=0.410, 95: 0.387-0.435], age ≥45 (compared with age<45, a=1.506, 95: 1.193-1.901), illiterate (compared with having high school education or above, a=0.904, 95: 0.832-0.982), unmarried (compared with divorced or widowed, a=0.896, 95: 0.848-0.946), through heterosexual transmission (compared with homosexual transmission, a=0.555, 95: 0.487-0.632), ethnic minorities (compared with Hans, a=1.185, 95: 1.114-1.262), and farmers/migrant workers (compared with domestic/unemployed,a=0.874, 95: 0.834-0.916,) ., were related to the survival time of HIV/AIDS, in Guizhou province. The mortality rate of HIV/AIDS in Guizhou province appeared relatively high, but with no obvious downward trend seen in the last years. Factors as being male, age ≥45, low education level, ethnic minorities, CD(4)<200 cells/μl were identified as related to the HIV/AIDS survival time. We would suggest that treatment and follow-up management programs should be strengthened to improve the quality of life among these patients.